Martifur

Nitrofurantoin is a synthetic nitrofuran-class antibiotic approved by the U.S. Food and Drug Administration in 1953 for treating and preventing uncomplicated lower urinary tract infections (UTIs) caused by susceptible bacteria.[1][2] It achieves bactericidal activity through reduction to reactive intermediates that damage bacterial macromolecules, including DNA, RNA, proteins, and cell walls, via inhibition of enzymes like acetyl coenzyme A and disruption of aerobic energy metabolism.[3][4] Primarily concentrated in urine due to rapid renal excretion, nitrofurantoin minimizes systemic exposure and preserves gut and broader microbiota, contributing to its sustained efficacy against common UTI pathogens like Escherichia coli despite rising antibiotic resistance elsewhere.[5][6] Common adverse effects include gastrointestinal upset such as nausea and diarrhea, while rare but serious risks—particularly with prolonged use—encompass pulmonary toxicity, peripheral neuropathy, and hepatotoxicity, necessitating caution in patients with renal impairment or extended therapy.[2][7] Its re-endorsement in guidelines amid multidrug-resistant infections underscores nitrofurantoin's role as a first-line option for uncomplicated cases in non-pregnant adults, balancing efficacy with a favorable resistance profile.[8][9]